By Neil Maclucas
ZURICH--Roche Holding AG (ROG.VX) on Friday said it was ending a
late-stage study of a drug to treat Alzheimer's disease, while a
separate study showed a breast-cancer treatment didn't yield
superior results to an existing treatment.
Basel-based Roche said it was discontinuing a study of
gantenerumab, a drug to treat patients with early Alzheimer's
disease after it yielded a safety profile similar to those in an
earlier study.
The company said it was "disappointed" with the results but that
it would use the study data for future research.
Roche had been testing gantenerumab as a potential agent for
delaying progression of early-stage Alzheimer's, a disease that
affects about 44 million people worldwide.
Separately, Roche said a late-stage trial to evaluate the
effectiveness of three of drugs on patients with HER2-positive
breast cancer yielded mixed results. Roche said its Kadcyla drug
used alone or in combination with its Perjeta treatment, and its
Herceptin drug used with chemotherapy all helped patients live for
a similar amount of time without the disease worsening.
However, the trials with Kadcyla weren't significantly better
than Herceptin used in combination with chemotherapy.
Roche said it had hoped the study would improve the survival
rate for advanced breast cancer without resorting to traditional
chemotherapy.
Write to Neil Maclucas at neil.maclucas@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires